Clinical Trial Update: The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study [Phase 2]

View source ↗

Summary

This Phase 2 feasibility trial evaluated whether administering exogenous melatonin can prevent delirium in patients with advanced cancer at risk of delirium.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Bruyère Health Research Institute. | Conditions: Cancer | Phase 2 | Status: COMPLETED